Literature DB >> 11212261

Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer.

M Campbell-Thompson1, I J Lynch, B Bhardwaj.   

Abstract

Colon cancer incidence and mortality rates are lower in females compared with males, and numerous epidemiological studies suggest that estrogen replacement therapy (ERT) reduces cancer risk in postmenopausal women. Two estrogen receptor (ER) subtypes, ERalpha and ERbeta, mediate genomic effects in target cells. The aim of this study was to determine the relative mRNA expression levels for ER subtypes and ERbeta isoforms in colon tumors, normal colonic mucosa, and colon cancer cell lines. ERalpha and ERbeta isoform mRNA levels were investigated in paired samples of colon tumors and normal mucosa from 26 patients using comparative reverse transcription-PCR and then Southern analyses. Constitutive steroid hormone receptor mRNA levels were determined for five colon adenocarcinoma cell lines using reverse transcription-PCR, and ERbeta levels were further studied in Caco-2 cells using Northern and Western analyses. ERbeta mRNA steady-state levels (relative to glyceraldehyde-3-phosphate dehydrogenase mRNA) were significantly decreased in colon tumors compared with normal mucosa in female patients. ERbeta1 and ERbeta2 isoform mRNA levels were significantly decreased in tumors from female patients, and ERbeta1 mRNA levels were also significantly lower in tumors from female patients compared with tumors from males. ERalpha mRNA levels were much lower than ERbeta levels and were similar between normal mucosa and tumor samples in both genders. ERbeta mRNA was detected in Caco-2, T84, and SW1116 cell lines and all lines were essentially negative for ERalpha mRNA. Caco-2 cells coexpressed ERbeta1, ERbeta2, and ERbeta5 mRNA, though a single protein transcript was observed. ERbeta protein was detected in normal colonic superficial epithelium, vascular smooth muscle and endothelium, and enteric neurons by immunohistochemistry. These data show that ERbeta is the predominant ER subtype in the human colon and that decreased levels of ERbeta1 and ERbeta2 mRNA are associated with colonic tumorigenesis in females. This information suggests that activation of ERbeta-mediated processes in the superficial colonic epithelium may have a role in the preventive effects observed for female gender and ERT usage.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11212261

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  117 in total

1.  ER beta inhibits proliferation and invasion of breast cancer cells.

Authors:  G Lazennec; D Bresson; A Lucas; C Chauveau; F Vignon
Journal:  Endocrinology       Date:  2001-09       Impact factor: 4.736

2.  Opposing action of estrogen receptors alpha and beta on tumor necrosis factor-alpha gene expression and caspase-8-mediated apoptotic effects in HA22T cells.

Authors:  Erh-Jung Huang; Cheng-Chung Wu; Shin-Da Lee; Juen-Hau Chen; Jer-Yuh Liu; Jiunn-Liang Ko; James A Lin; Min-Chi Lu; Li-Mien Chen; Chih-Yang Huang; Wei-Wen Kuo
Journal:  Mol Cell Biochem       Date:  2006-04-22       Impact factor: 3.396

3.  ERalpha and ERbeta expression and transcriptional activity are differentially regulated by HDAC inhibitors.

Authors:  V Duong; A Licznar; R Margueron; N Boulle; M Busson; M Lacroix; B S Katzenellenbogen; V Cavaillès; G Lazennec
Journal:  Oncogene       Date:  2006-03-16       Impact factor: 9.867

4.  Higher parity and earlier age at first birth are associated with lower risk of death from colon cancer.

Authors:  Chao-Hung Kuo; Chien-Chun Kuo; Hsiu-Yi Wu; Deng-Chyang Wu; Chun-Yuh Yang
Journal:  Cancer Sci       Date:  2012-07-04       Impact factor: 6.716

5.  Tamoxifen can reverse multidrug resistance of colorectal carcinoma in vivo.

Authors:  Li-Zong Shen; Yi-Bing Hua; Xue-Ming Yu; Qing Xu; Tao Chen; Jian-Hua Wang; Wen-Xi Wu
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

6.  Prospective cohort study of soy food intake and colorectal cancer risk in women.

Authors:  Gong Yang; Xiao-Ou Shu; Honglan Li; Wong-Ho Chow; Hui Cai; Xianglan Zhang; Yu-Tang Gao; Wei Zheng
Journal:  Am J Clin Nutr       Date:  2008-12-10       Impact factor: 7.045

Review 7.  Female fertility and colorectal cancer.

Authors:  Constantine P Spanos; Apostolos Mamopoulos; Apostolos Tsapas; Theodore Syrakos; Dimitris Kiskinis
Journal:  Int J Colorectal Dis       Date:  2008-05-06       Impact factor: 2.571

8.  Impact of oral bisphenol A at reference doses on intestinal barrier function and sex differences after perinatal exposure in rats.

Authors:  Viorica Braniste; Aurore Jouault; Eric Gaultier; Arnaud Polizzi; Claire Buisson-Brenac; Mathilde Leveque; Pascal G Martin; Vassilia Theodorou; Jean Fioramonti; Eric Houdeau
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

9.  Hormone therapy in relation to survival from large bowel cancer.

Authors:  Polly A Newcomb; Victoria M Chia; John M Hampton; V Paul Doria-Rose; Amy Trentham Dietz
Journal:  Cancer Causes Control       Date:  2008-11-09       Impact factor: 2.506

10.  An association between the PTGS2 rs5275 polymorphism and colorectal cancer risk in families with inherited non-syndromic predisposition.

Authors:  Jason Ross; Linda Lockett; Diana Brookes; Bruce Tabor; Konsta Duesing; Michael Buckley; Trevor Lockett; Peter Molloy; Finlay Macrae; Graeme Young; Ignacio Blanco; Gabriel Capella; Garry N Hannan
Journal:  Eur J Hum Genet       Date:  2013-03-27       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.